Celltrion receives European Commission approval of Omlyclo ® (CT-P39), the first and only omalizumab biosimilar approved in Europe
Celltrion today announced that the European Commission (EC) has approved Omlyclo® (CT-P39), an omalizumab biosimilar referencing Xolair®. Omlyclo® is approved for the treatment of allergic asthma, chronic spontaneous urticaria (CSU), and chronic rhinosinusitis with nasal polyps (CRSwNP).
The EC approval of Omlyclo® follows the recommendation for marketing authorisation issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in March 2024.
The decision is based on clinical evidence, including results from a global Phase III clinical trial designed to evaluate the efficacy, safety and pharmacokinetics of Omlyclo® compared to the reference product Xolair® in patients with CSU up to Week 40.
“For more than two decades, omalizumab, a blockbuster monoclonal antibody anti-IgE, has revolutionised the management of chronic immune-mediated inflammatory diseases,” said Professor Marcus Maurer, Professor of Dermatology and Allergy, Co-Director for the Fraunhofer Site for Immunology and Allergology of the Fraunhofer Translational Medicine and Pharmacology ITMP and Executive Director for the Institute of Allergology, Charité - Universitätsmedizin Berlin, Germany. “The development of a biosimilar of omalizumab is a welcome solution to help alleviate some challenges with treatment access. The recently approved treatment Omlyclo® has a comparable efficacy, safety and immunogenicity profile to Xolair®.”
“Immunological conditions such as asthma can have a significant impact on the day-to-day lives of patients without appropriate treatment and care. This is why we are pleased to receive the first EC approval for an omalizumab biosimilar in Europe, an important step towards improving patient access to treatment. As we continue to expand our biosimilar offerings across the globe, building on our immunology and oncology product portfolio, we look forward to making a meaningful difference for patients living with immunological conditions,” said Hyoung-Ki Kim, Vice Chairman at Celltrion.
Omlyclo® is Celltrion’s sixth biosimilar, besides Remsima® SC, a subcutaneous formulation of infliximab, approved for use in the EU, following the approval of Remsima® (biosimilar infliximab), Truxima® (biosimilar rituximab), Herzuma® (biosimilar trastuzumab), Yuflyma® (biosimilar adalimumab), and Vegzelma® (biosimilar bevacizumab). Omlyclo® is currently under review by the U.S. Food and Drug Administration (FDA), following the submission in March 2024.
About OMLYCLO® (CT-P39, biosimilar omalizumab)
Omlyclo® is the first European Commission (EC) approved anti-IgE antibody biosimilar referencing Xolair® (omalizumab). In the EU, Omlyclo® is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP).
About Celltrion
Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. The company’s solutions include world-class monoclonal antibody biosimilars such as Remsima®, Truxima® and Herzuma®, providing broader patient access globally. Celltrion has also received U.S. FDA and EC approval for Vegzelma® and Yuflyma®, FDA approval for Zymfentra™, and EC approval for Remsima® SC. To learn more, please visit www.celltrion.com/en-us.
FORWARD-LOOKING STATEMENT
Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws.
These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.
In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control.
Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.
Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this presentation are based upon what management of Celltrion Inc. and its subsidiaries believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Trademark
Xolair® is a registered trademark of Novartis AG.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521556727/en/
Contact information
Holly Barber
hbarber@hanovercomms.com
+44 (0) 7759 301620
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hero MotoSports Team Rally Secures an Impressive 7 th Place Overall Finish at Dakar Rally 202517.1.2025 21:31:00 CET | Press Release
Hero MotoSports Team Rally, the motorsport team of the world’s largest manufacturer of motorcycles and scooters - Hero MotoCorp, has successfully completed the Dakar Rally 2025, reinforcing its position as a formidable force in the world’s toughest rally. The team completed this year’s rally at overall 7th position, registering its second best Dakar performance in nine years, after it finished 2nd overall at the world’s toughest rally last year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250117472643/en/ Hero MotoSports at Dakar Rally Stage 12 (Photo: Business Wire) The team’s young Chilean rider, Nacho Cornejo, delivered a stellar performance, maintaining top-10 standings throughout the rally and securing an overall 7th place finish. Nacho showcased remarkable grit and determination, demonstrating his consistency across the stages. Since Stage 1, he remained in the top-10, climbed to 7th place in Stage 8, and held on to
Qualcomm Announces Quarterly Cash Dividend17.1.2025 15:00:00 CET | Press Release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.85 per common share, payable on March 27, 2025, to stockholders of record at the close of business on March 6, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Our proven solutions drive transformation across major industries, and our Snapdragon® branded platforms power extraordinary consumer experiences. Building on our nearly 40-year leadership in setting industry standards and creating era-defining technology breakthroughs, we deliver leading edge AI, high-performance, low-power computing, and unrivaled connectivity. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business, QTL, and the vast majority
Jefferies Clients, Shareholders and Employees Contribute $10 Million to Charities Supporting Los Angeles Wildfire Relief17.1.2025 14:00:00 CET | Press Release
Jefferies announced today that it will donate $10 million to charities providing aid for first responders and the people and communities impacted by the wildfires across Los Angeles. The donation includes funds from Jefferies, voluntary contributions from its nearly 6,000 worldwide employees, and proceeds from the firm’s January 16 Doing Good Global Trading Day, which set aside 100% of net global trading commissions for charities. Rich Handler, CEO, and Brian Friedman, President of Jefferies, said: “We are so grateful for how the Jefferies network stepped up to support those in need in Los Angeles. These wildfires have inflicted heartbreaking devastation on communities and so many families, and we hope this donation will help deserving charities provide urgently needed relief.” Organization Charity Description Allocation Los Angeles Fire Department Foundation The LAFD is actively seeking funds to equip LAFD members battling wildfires with tools and supplies. $2,000,000 All Hands and He
SLB Announces Fourth-Quarter and Full-Year 2024 Results, Increases Dividend and Initiates $2.3 billion in Accelerated Share Repurchases17.1.2025 12:50:00 CET | Press Release
SLB (NYSE: SLB) today announced results for the fourth-quarter and full-year 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115789214/en/ The exterior of the SLB headquarters in Houston, Texas. (Photo: Business Wire) Fourth-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeDec. 31, 2024Sept. 30, 2024Dec. 31, 2023SequentialYear-on-yearRevenue $9,284 $9,158 $8,990 1% 3% Income before taxes - GAAP basis $1,387 $1,507 $1,433 -8% -3% Income before taxes margin - GAAP basis 14.9% 16.5% 15.9% -151 bps -100 bps Net income attributable to SLB - GAAP basis $1,095 $1,186 $1,113 -8% -2% $0.77 $0.83 $0.77 -7% - Adjusted EBITDA* $2,382 $2,343 $2,277 2% 5% Adjusted EBITDA margin* 25.7% 25.6% 25.3% 8 bps 33 bps Pretax segment operating income* $1,918 $1,902 $1,868 1% 3% Pretax segment operating margin* 20.7% 20.8% 20.8% -11 bps -12 bps Net income attributable to SLB, excluding charges & credits*
Perpetual Atomics and QSA Global Sign Collaboration Agreement17.1.2025 11:03:00 CET | Press Release
Perpetual Atomics is excited to announce this collaboration, which will enable the processing of americium into sealed sources for use in radioisotope power systems, including radioisotope heater units (RHUs) and radioisotope thermoelectric generators (RTGs). This partnership is another step toward supporting sustainable and reliable power solutions for some of the most challenging environments in space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250107229344/en/ Perpetual Atomics Team gathered at the University of Leicester (Photo: Business Wire) A University of Leicester spinout, Perpetual Atomics brings over 20 years of expertise in space nuclear power systems and exploration, delivering innovative, reliable solutions for powering space missions in extreme environments, including "surviving the night." QSA Global, with its extensive expertise in designing and producing commercial radioisotope sealed sources for indust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom